This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:
“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.
Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."
For information, full details of the votes received were as follows:
At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”
Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:
“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.
Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."
For information, full details of the votes received were as follows:
At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”
Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:
“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.
Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."
For information, full details of the votes received were as follows:
At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”
Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:
“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.
Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."
For information, full details of the votes received were as follows:
At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”
Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:
“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care. In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.
Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."
For information, full details of the votes received were as follows:
At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:
“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”
